Cell Therapy News/Articles, page-9341

The USA market for Mesoblast’s ADR’s was very strong on Friday, and I would say the Australian article was partially responsible for that. The shares would have gone higher, however there were around 800 options at 7.50 expiring that day, so that kept the price around 7.50 in the afternoon trading session, although they had risen to 7.70 in the morning (which is a hair under $2 AUS).

Reading tea leaves, the FDA discussions on aGVHD are progressing and there is a hint that the appeals process is working. Another tea leaf is that NOVARTIS are not going away, and Itescu’s friend is very bullish...

SILVIU ITESCU:
“THE SURVIVAL BENEFIT WE ARE NOW SEEING IS BEYOND MY WILDEST DREAMS,” ITESCU SAYSIF THAT WAS THE ONLY THING THEY WERE INTERESTED IN, THEY WOULD HAVE WALKED FIVE MONTHS AGO.

WAISLITZ (Investor & Friend):
THE DREAM THAT THE CASH-BURNING BIOTECH IS ON THE CUSP OF A NUMBER OF APPLICATIONS THAT ARE MULTI-BILLION-DOLLAR MARKETS. “I UNDERSTAND THE RISK-REWARD SIDE OF THIS AND THE VOLATILITY OF THE JOURNEY. I AM THERE FOR BOTH THE IMPACT ON HUMAN LIVES AND THE FINANCIAL RETURNS”.
“I AM THERE TO MAKE FIVE, 10 OR 20 TIMES MY MONEY FROM HERE, EVEN THOUGH I HAVE BANKED GOOD GAINS ALREADY.”